Click here to create your personal news page. The news that appears on Shire plc will appear there and be constantly updated. You can then modify the page, share it with your friends, or export it and have it appear elsewhere.

You can also create a personal news page and follow the news that interests you by clicking on the tab labelled 'New page'.
 

topics : related - allExplore

Wikio Shopping

  1. 1. Baby & Nursery
  2. 2. Car/Motor Bike
  3. 3. Communication
  4. 4. Computers
  5. 5. Electronics
  6. 6. Entertainment
  7. 7. Fashion & Lingerie
  8. 8. Finance
  9. 9. Gifts & Gadgets
  10. 10. Health & Beauty
  11. 11. Home & Garden
  12. 12. Household Appliances
  13. 13. Sport & Fitness
  14. 14. Travel
  15. 15. Video Games

New products

  1. 1. Western Digital ShareSpace 4TB
  2. 2. Sapphire Radeon HD 4550
  3. 3. LG KP500
  4. 4. Dell S2309W
  5. 5. Samsung Pixon
  6. 6. Shuttle D 1000H
  7. 7. Philips M200
  8. go to Shopping

Participate



Shire plc


Sort by : relevance - date - popularity
+Vote!

Change of Name to Shire plc

DUBLIN, Ireland, October 1 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the approval by shareholders at the Annual General Meeting on September 24, 2008, the Company has changed its name to Shire plc with effect from today. Shire plc's ticker symbols on the London Stock Exchange and NASDAQ and the ISIN...

+Vote!

The Report of this Company

Dear Vic Fabe I have another work for your writers to write for me. I have attached the description where all of the details of the coursework explained. The company of my choice is Shire PLC pharmaceutical company. The report of this company should include topics that we have covered...

+Vote!

Long-term safety data on Lialda published in leading GI journal

( Shire plc ) Shire Ltd., the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study of ulcerative colitis drug Lialda.

+Vote!

Analysis Of Ulcerative Colitis (UC) Time To Symptom Resolution Data From Pivotal Study Of LIALDA (mesalamine) Presented At DDW

A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, NASDAQ: SHPGY) ulcerative colitis (UC) drug, LIALDATM, will be presented today at Digestive Disease Week (DDW). Study 302 (further referred to as "Kamm study," led by Dr Michael A.

+Vote!

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of ...

[NEWS] SAN DIEGO, May 20 /PRNewswire-FirstCall/ — A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA™, will be presented today at Digestive Disease Week (DDW). Study 302 (further referred to as “Kamm study,” led by Dr Michael A. Kamm, from St Mark’s Hospital in London, UK), demonstrated LIALDA...

+Vote!

Shire Launches Nationwide Adult ADHD Mobile Awareness Tour

PHILADELPHIA, May 12 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced the launch of a 13-city mobile screening initiative for adults with Attention Deficit Hyperactivity Disorder (ADHD), a psychiatric disorder that affects approximately 4.4 percent of the U.S.

+Vote!

Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans

BASINGSTOKE, England and PHILADELPHIA, May 9 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announces that ordinary shareholders approved the scheme of arrange...

1Vote!

VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day.

+Vote!

Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the ...

[NEWS] VYVANSE demonstrated significant improvement in ADHD symptoms in adults WASHINGTON, May 8 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all...

1Vote!

Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms

Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).

+Vote!

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) Demonstrated Significant Efficacy In Reducing ADHD Symptoms

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).

+Vote!

New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA(TM), Offered ADHD Symptom Control For 12 Months

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA™ (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).

1Vote!

New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA(TM) (methylphenidate Transdermal System), Offered ADHD Symptom Control For 12 Months

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).

+Vote!

Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms

Shire plc, the global specialty biopharmaceutical company,presented today at a major scientific meeting findings from analyses ofpivotal trial results of an investigational once-daily medication, INTUNIV (guanfacine extended release), a selective alpha-2A-agonist. The data demonstrated that INTUNIV showed significant efficacy in reducing Attention Deficit Hyperactivity Disorder symptoms for patients...

+Vote!

Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association...